ReviewFrontiers in oncology2025
AI-powered advances in type II endometrial cancer: global trends and African contexts.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The advent of artificial intelligence (AI) in oncology has opened new avenues for enhancing the diagnosis, treatment, and prognosis of type II endometrial cancers (ECs), which account for the majority of EC-related deaths globally. With rising incidence and increasing concerns in Africa, type II ECs are often detected in advanced stages, exhibit aggressive progression, and resist conventional therapies. Despite these characteristics, they are still treated similarly to type I ECs, which are less aggressive and more treatment-responsive. Currently, no specific targeted therapies exist for type II ECs, creating an urgent need for innovative treatment options. Methods: This review examines the integration of AI-powered approaches in the care of type II ECs, focusing on their potential to address rising incidence and disparities in Africa. It explores AI-driven diagnostic tools, tailored therapeutic options, and ongoing innovative projects, including efforts to integrate indigenous knowledge into AI applications. Results: AI-powered therapeutic options tailored to the unique clinical profiles of type II EC patients show promise for developing targeted therapies. Several innovative projects are underway, leveraging AI to meet Africa's unique healthcare challenges. These applications demonstrate significant potential to reduce healthcare disparities and improve patient outcomes, especially in resource-limited settings. Discussion: This review highlights the transformative potential of AI technologies in improving the diagnosis, treatment and management of type II ECs, particularly in Africa, where healthcare disparities are significant. Through the integration of AI in the type II EC care continuum, challenges in African healthcare can be overcome. Innovative projects, leveraging AI to meet the continent's challenges, have the potential to improve patient outcomes. AI-driven therapies hold the key to personalized oncologic care, and indigenous African knowledge can be used to develop Afrocentric healthcare solutions. In Future, with continued research and the development of robust frameworks and transparent algorithms, investment and collaboration, the potential of AI in Type II EC will be realized.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.